U.S. drug-pricing push forces Novartis AG and pharma to rethink U.S. commercial and R&D strategy

Policy push forces pharma to reassess U.S. strategy

Drug-pricing language in a recent U.S. government funding bill is prompting multinational drugmakers, including Novartis AG, to recalibrate commercial and R&D plans as Washington intensifies its focus on lowering medicine costs. The provision is driving industry attention toward pricing negotiations, formulary access and long-term revenue assumptions in the largest pharmaceutical market. Companies are evaluating how new rules could change launch strategies for high-cost specialty drugs and biologics that account for a large share of profit.

Novartis, as a major global pharmaceuticals group with substantial U.S. sales, is reassessing portfolio priorities and payer engagement in response to the policy shift. The company is weighing options that include adjusting launch price expectations, expanding value-based contracting, increasing investment in indications with clear cost-offsets, and accelerating launches in non-U.S. markets where pricing pressures differ. Novartis is also likely to revisit its pipeline prioritisation, focusing resources on therapies with demonstrable clinical and economic benefit that can withstand scrutiny from payers and policymakers.

The measure is also prompting broader industry moves that could affect innovation dynamics. Executives and investors expect a sharper focus on cost-effectiveness evidence, outcomes-based reimbursement models, and collaborations with health systems to demonstrate real-world benefit. While some firms may trim early-stage programs that lack clear commercial pathways under tighter pricing, others may pursue efficiencies in development or redirect capital into areas such as precision medicines and cell and gene therapies where differentiation can command premium pricing under value frameworks.

Market and commodity backdrop remains cautious

Financial markets are showing risk-off sentiment, with technology and precious metals leading declines and gold and silver prices falling sharply. Easing geopolitical tensions between the U.S. and Iran soften oil markets, while Asian equities retreat amid wider selling pressure.

Policy and supply chains draw attention beyond pricing

Separately, the U.S. State Department is convening miners from around 50 countries on critical minerals — a focus likely to shape supply chains for technology and energy sectors. At the same time, anxiety over AI-driven disruption weighs on software and private equity names as investors and policy makers parse long-term implications.